The combination of NPRL2 and cisplatin can enhance and resensitize the response of cisplatin-nonresponders to cisplatin treatment through the strong activation of the DNA damage checkpoint pathway, leading to cell cycle arrest in the G2/M phase and induction of apoptosis (Figure 8) and suggesting that NPRL2 gene delivery for cisplatin-resistant patients may safely enhance the efficacy of cisplatin in the treatment of lung cancer. This evidence concerns the gene NPRL2 and lung cancer.